Liverpool School of Tropical Medicine

Clinical Study Finds Aetrex Orthotics Reduce Pain and Fear of Falling for Seniors

Retrieved on: 
Thursday, September 14, 2023
Research, Seniors, Other Retail, Clinical Trials, Health, Consumer, General Health, Retail, Science, Foam, DSM-IV codes, NRS, Human, Liverpool School of Tropical Medicine, Hip, University of Liverpool, Perception, Foot, Ageing, University of Liverpool School of Medicine, Proprioception, Woman, Employment, Multimedia, Trial of the century, Pain, Physical, Muscle weakness, Synthetic control method, Aintree University Hospital, Risk, University, Randomized controlled trial, Metatarsal bones, Shoe, Fear of falling, Mental health, Falling, Knee, Poultry farming, Geriatrics

A recent study found that Aetrex Premium Memory Foam Orthotics , both with and without metatarsal support, are clinically proven to reduce common sources of pain (i.e., back, foot, hip, knee and ankle pain) and the fear of falling for seniors.

Key Points: 
  • A recent study found that Aetrex Premium Memory Foam Orthotics , both with and without metatarsal support, are clinically proven to reduce common sources of pain (i.e., back, foot, hip, knee and ankle pain) and the fear of falling for seniors.
  • View the full release here: https://www.businesswire.com/news/home/20230914845282/en/
    Left: Aetrex Premium Memory Foam Orthotic Right: Aetrex Premium Memory Foam Orthotic with Metatarsal Pad (Graphic: Business Wire)
    Both foot pain and fear of falling are obstacles to healthy aging.
  • Seniors who report a fear of falling more than double their risk of actually falling.
  • The study also shows orthotics reduce the fear of falling in seniors.

Innovation in Resistance Management: VECTRONTM T500, a New Vector Control Product, is Prequalified by the World Health Organization (WHO)

Retrieved on: 
Tuesday, March 14, 2023
Health, Chemicals, Plastics, Infectious Diseases, Manufacturing, Other Health, Research, Science, History, Public sector, Rotation, Insecticide, Bill, ISIN, PDP, Mark R. Dybul, Agency, Sale, Toxicity, PQ, USAID, IVCC, IRS, Tropical medicine, Aluminium, Multimedia, Malaria, IRAC, Swiss Agency for Development and Cooperation, Development, Liverpool School of Tropical Medicine, The Global Fund to Fight AIDS, Tuberculosis and Malaria, LSTM, Unitaid, Public, PPM, Mitsui Chemicals, Fine chemical, Vaccine

VECTRONTM T500 will support the rotation of insecticides in line with best practice insecticide resistance management, which is critical to preserve the long-term efficacy of vector control tools.

Key Points: 
  • VECTRONTM T500 will support the rotation of insecticides in line with best practice insecticide resistance management, which is critical to preserve the long-term efficacy of vector control tools.
  • VECTRONTM T500 has outstanding efficacy against malaria vector mosquitoes including strains and populations resistant to pyrethroids and some other insecticides.
  • Mitsui Chemicals Agro will launch VECTRONTM T500 in sub-Saharan African countries from 2023 in line with locally required conditions of use.
  • OZAWA says: “Mitsui Chemicals Agro is an R&D driven chemical company, that has been developing malaria vector control products to save human lives.

The Galien Foundation Debuts 2022 Prix Galien UK Award Candidates in "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Medical Technology" and "Best Digital Health Solution" Categories

Retrieved on: 
Monday, May 2, 2022
Hygiene, Education, Foundation, London School of Hygiene & Tropical Medicine, Queen Mary University of London, College, Liverpool School of Tropical Medicine, Edinburgh, Therapy, University of Liverpool, University of Edinburgh College of Medicine and Veterinary Medicine, University of Edinburgh, Veterinary medicine, Respiratory Medicine, Social media, Paganini Competition, University, Health, Nobel Prize, Dentistry, Pharmaceutical industry, Medicine, Biostatistics, Pediatric nursing

LONDON, May 2, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced the 2022 Prix Galien UK Award candidates for "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Medical Technology" and "Best Digital Health Solution." Winners will be announced during the Prix Galien UK Awards Ceremony on 12 May at the Natural History Museum in London.

Key Points: 
  • Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.
  • The Foundation oversees and directs activities in the UK for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa.
  • The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology.
  • Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

CN Bio and iiCON Announce COVID-19 Research Collaboration

Retrieved on: 
Tuesday, November 9, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Clinical Trials, Efficiency, University, Adoption, Liverpool School of Tropical Medicine, OOC, Industry, Therapy, PD, Infection, CL3, Heart, Department, 3D, Organ (anatomy), Severe acute respiratory syndrome coronavirus 2, COVID-19, Research, MPS, The IIconics, LSTM, Human, Partnership, University of Liverpool, Company, Tropical medicine, Environment, Innovation, Lung, CN, Pharmaceutical industry

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.
  • Under the terms of the agreement, iiCON lead partner, LSTM, a world-leading institute for infectious disease research, will independently validate CN Bios novel lung and lung-liver models, designed to advance novel SARS-CoV-2 drug discovery and development.
  • This collaboration will provide access to the institutes world-leading expertise in infectious disease research, in addition to the consortiums outstanding industry links.
  • As part of the consortium, LSTM is delighted to be entering into this key agreement with CN Bio.

Innova Medical Group Gifts £10m To Launch Global Pandemic Institute In Liverpool

Retrieved on: 
Monday, September 13, 2021

Innova's donation provides the startup capital required to establish the Institute, alongside support from the Liverpool City Council, The University of Liverpool, Liverpool John Moores University, the Liverpool School of Tropical Medicine, and KQ Liverpool.

Key Points: 
  • Innova's donation provides the startup capital required to establish the Institute, alongside support from the Liverpool City Council, The University of Liverpool, Liverpool John Moores University, the Liverpool School of Tropical Medicine, and KQ Liverpool.
  • The result will allow the world to accelerate global response to future pandemic events, to unify global intelligence and to dramatically increase the impact of pandemic research on the global society.
  • "Liverpool is perfectly placed for this exciting initiative and we appreciate Innova's leadership in establishing the Pandemic Institute and the generous gift to Liverpool."
  • Innova Medical Group is a global health screening and diagnostic innovator driven to dramatically improve health outcomes worldwide with equitable, high-value testing solutions.

Innova Medical Group Gifts £10m To Launch Global Pandemic Institute In Liverpool

Retrieved on: 
Monday, September 13, 2021

PASADENA, Calif. and LIVERPOOL, England, Sept. 13, 2021 /PRNewswire/ -- Innova Medical Group, a global health innovator and the world's largest provider of rapid antigen tests, has announced a £10 million donation for the launch of The Pandemic Institute, a global centre of excellence to help the world prevent, prepare, and respond more effectively to future pandemics. The Institute is headquartered in Knowledge Quarter Liverpool (KQ Liverpool). 

Key Points: 
  • Innova's donation provides the startup capital required to establish the Institute, alongside support from the Liverpool City Council, The University of Liverpool, Liverpool John Moores University, the Liverpool School of Tropical Medicine, and KQ Liverpool.
  • The result will allow the world to accelerate global response to future pandemic events, to unify global intelligence and to dramatically increase the impact of pandemic research on the global society.
  • "Liverpool is perfectly placed for this exciting initiative and we appreciate Innova's leadership in establishing the Pandemic Institute and the generous gift to Liverpool."
  • Innova Medical Group is a global health screening and diagnostic innovator driven to dramatically improve health outcomes worldwide with equitable, high-value testing solutions.

The University of Liverpool, Liverpool School of Tropical Medicine, and Southampton Clinical Trials Unit: Search for Effective COVID-19 Treatments - Novel Clinical Trial Platform Launched to Test New Treatments in Liverpool

Retrieved on: 
Tuesday, July 7, 2020
Health, University of Liverpool, Liverpool School of Tropical Medicine, University of Southampton, Clinical trial

The AGILE initiative is a collaboration between the University of Liverpool, Liverpool School of Tropical Medicine, Southampton Clinical Trials Unit, University of Southampton, and Lancaster University, as well as other partners.

Key Points: 
  • The AGILE initiative is a collaboration between the University of Liverpool, Liverpool School of Tropical Medicine, Southampton Clinical Trials Unit, University of Southampton, and Lancaster University, as well as other partners.
  • AGILE has been developed by Infectious Diseases clinicians, clinical and pre-clinical pharmacologists, clinical trials specialists and statisticians.
  • Liverpool School of Tropical Medicine (LSTM) is the world's oldest centre of excellence in tropical medicine and international public health.
  • Southampton Clinical Trials Unit (SCTU) is based at Southampton General Hospital within the University of Southampton and is a UK Clinical Research Collaboration registered Clinical Trials Unit.

IAVI and Liverpool School of Tropical Medicine to Partner in Scientific Consortium for New Snakebite Therapies

Retrieved on: 
Thursday, May 16, 2019
Health, AIDS, Clinical trials, Pharmaceutical, Other Health, Philanthropy, Research, Other Science, Other Philanthropy, Science, Medical specialties, Medicine, Health, International AIDS Vaccine Initiative, Neutralizing antibody, Liverpool School of Tropical Medicine, Broadly neutralizing HIV-1 antibodies, HIV vaccine, Antivenom, Tropical medicine

The International AIDS Vaccine Initiative (IAVI) and the Liverpool School of Tropical Medicine (LSTM) today announced a new global research consortium, the Scientific Research Partnership for Neglected Tropical Snakebite (SRPNTS).

Key Points: 
  • The International AIDS Vaccine Initiative (IAVI) and the Liverpool School of Tropical Medicine (LSTM) today announced a new global research consortium, the Scientific Research Partnership for Neglected Tropical Snakebite (SRPNTS).
  • IAVI will coordinate the snakebite research partnership with funding provided by DFID over three years.
  • The consortium will employ IAVI technologies and capabilities used originally for discovering HIV-specific broadly neutralizing antibodies (bNAbs) to develop new antivenom therapies.
  • Liverpool School of Tropical Medicine (LSTM) is the world's oldest center of excellence in tropical medicine and international public health.